#ipf highlights

Idiopathic Pulmonary Fibrosis Treatment

Key Points

BI 1015550 represents the first molecule in the phosphodiesterase 4B (PDE4B) inhibitors studied for IPF.

The drug has combined antifibrotic and anti-inflammatory effects.

Either administered alone or in combination with antifibrotic medication, BI 1015550 helps in slowing down the worsening of lung function in people with IPF

Idiopathic Pulmonary Fibrosis (IPF) is a fatal interstitial lung disease. As the morbidity and mortality rates associated with IPF remain high, prompt Idiopathic Pulmonary Fibrosis treatment is critical to safeguard individuals’ lung function, reduce the risk of acute exacerbations, and improve outcomes. Currently, there are only two FDA-approved drugs for Idiopathic Pulmonary Fibrosis treatment, including Esbriet (cytokine inhibitor) developed by Hoffmann-La Roche and Ofev (tyrosine kinase inhibitor) developed by Boehringer Ingelheim.

With prior experience in the Idiopathic Pulmonary Fibrosis treatment, Boehringer is accelerating the development of another drug named BI 1015550 with a novel mechanism of action to treat IPF patients. BI 1015550 represents the first molecule in the class of phosphodiesterase 4B (PDE4B) inhibitors studied for Idiopathic Pulmonary Fibrosis treatment and other progressive fibrosing interstitial lung diseases (ILDs). The drug has combined antifibrotic and anti-inflammatory effects. It recently received Breakthrough Designation by the US FDA in February 2022 for Idiopathic Pulmonary Fibrosis treatment.

At the recently held American Thoracic Society (ATS) International Conference, the Company has published the safety and efficacy of BI 1015550 18 mg twice daily in IPF patients (Phase II (NCT04419506)). In the 12-week data, the drug has shown promising results in both groups, i.e., the rate of lung function decline in patients who were not on approved antifibrotics and those who were taking existing antifibrotic therapy.

The primary study outcome was the change in FVC (measured in mL) from baseline at week 12. In patients who were not on approved antifibrotics, the median change in FVC was increased by 5.7 mL for BI 1015550 and decreased by 81.7 mL for the placebo arm; in patients who were already on antifibrotic therapy, the median change in FVC was increased by 2.7 mL for BI 1015550 and decreased by 59.2 mL for the placebo arm. It was found that BI 1015550 had a >98% probability of being superior to placebo in slowing down the worsening of lung function in IPF patients. Over 12 weeks, the trial also met its secondary goal, and the proportion of patients experiencing any adverse event (AE) was greater in patients treated with BI 1015550 compared to placebo in both AF patients (73% versus 68%) and non-AF (65% versus 52%).

Overall, the study concluded that BI 1015550 at 18 mg BID, either given alone or with antifibrotic medication, preserved lung function in IPF patients. The Company expects to initiate a phase III program for the drug later this year. The drug can be a promising oral therapeutic option for Idiopathic Pulmonary Fibrosis treatment and other fibro-proliferative illnesses due to its preferential inhibition of PDE4B and anticipated enhanced tolerability in humans and its anti-inflammatory and antifibrotic properties. Suppose this drug gets approval in the upcoming years. In that case, it will compete with already approved treatments, and Boehringer Ingelheim might continue to be a leader in the Idiopathic Pulmonary Fibrosis market.

For more detailed analysis, visit at Idiopathic Pulmonary Fibrosis market.

For more detailed information, visit the ATS Conference 2022.

Explore our recently launched abstracts:

An evolving Treatment Paradigm for PAH

The Future of Pulmonary Rehabilitation: Evolving Patterns & Types discussed in ATS Conference, 2022

MRx-4DP0004- a next-generation drug for management of Severe Asthma

Riociguat potential benefit over PDE5i in PAH

P492 –New TQT Analysis by Verona Pharma supports planned NDA Submission

Report Offerings by DelveInsight:

Adalimumab Biosimilars Insight

DelveInsight’s, “Adalimumab– Biosimilar Insight, 2022,” report provides comprehensive insights about 35+ companies and 35+ marketed and pipeline drugs in Adalimumab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Mucopolysaccharidosis Market

DelveInsight's "Mucopolysaccharidosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Mucopolysaccharidosis, historical and forecasted epidemiology as well as the Mucopolysaccharidosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Metastatic Cutaneous Squamous Cell Cancer Market

DelveInsight's "Metastatic Cutaneous Squamous cell cancer Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Metastatic Cutaneous Squamous cell cancer, historical and forecasted epidemiology as well as the Metastatic Cutaneous Squamous cell cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Hyperlipidemia Market

DelveInsight's "Hyperlipidemia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Hyperlipidemia, historical and forecasted epidemiology as well as Hyperlipidemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Medical Marijuana Market Insight

DelveInsight's "Medical Marijuana- Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Medical Marijuana, historical and forecasted epidemiology as well as the Medical Marijuana market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To know more about our Competitive Services, Click here: Pharma Competitive Intelligence

Blog Section:

How Metaverse is Set to Transform the Healthcare Dynamics?

Evaluating the Essential Factors Building the Value-Based Healthcare Model

Cybersecurity in Healthcare: Major Threats and Challenges

What are Monoclonal Antibodies and How Can They Treat COVID-19?